Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000288700 refers to a novel RNA transcript identified from large-scale transcriptome analysis, likely representing a long non-coding RNA (lncRNA). It has no established protein-coding function, nor is it well-characterized regarding biological role or disease association. Some studies have reported its altered expression in the context of peripheral blood from Parkinson’s disease patients, suggesting possible—but unproven—utility as a biomarker, but it is not an established therapeutic target nor classified in any major molecular target family[1][3][5]. The name "novel transcrpt" is non-standard and appears to be a typo. Summary: ENSG00000288700 ("novel transcript") is a poorly characterized, likely non-coding RNA with no evidence of being a therapeutic target, and carries an incorrect and non-standard designation. Existing information is insufficient for standard molecular and clinical annotation, beyond its preliminary transcriptomic identification[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript (no established human gene or protein name).